Document:

Exhibit 4.4

    

     

      

    
      	
              
                

              

            	
              
                Modi'in Technology Park

                2 HaMa'ayan Street

                Modi'in 7177871, Israel

                 

                

                
                  Phone: 972-8-642-9100

                  Fax:      972-8-642-9101

                  web:      www.BioLineRx.com

                

              

            

    

     

    

    September 24, 2020

    

    

    Re: Amendment to Employment Agreement

    

    

    Dear Mali:

    

    

    This letter shall serve as an amendment (the "Amendment") to that certain Employment Agreement, dated September 16, 2009, by and
      between BiolineRx Ltd. ("Bioline") and Mali Zeevi (the "Employee"), as amended, (the "Employment Agreement"). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Employment Agreement.

     

    Bioline and Employee hereby mutually agree to the following revisions to the Employment Agreement:

    

    

    Section 5.2 of the Employment Agreement shall be replaced with the following:

    

    

    "5.2          Termination.

     

      

                   (a)        In the event of termination without Cause (as defined below) by Bioline of Employee's employment, Bioline may terminate the Employment Agreement by giving the Employee prior
      written notice of 180 days.

     

    

    
                     (b)        In the event Employee resigns his employment for any reason that would constitute constructive dismissal under Israeli law, Employee may terminate the Employment Agreement by giving Bioline prior written notice of 60
        days, but will be entitled to be compensated for a Notice Period of 180 days.

       

      

                     (c)        In the event Employee resigns his employment for any reason other than as stated in section (b) above, Employee may terminate the Employment Agreement by giving Bioline prior written notice of 60 days. 

       

     

    Each of the notice periods in this Section 5.2 shall be deemed a "Notice Period" for the purpose of Section 5.4 below."

    

    

    
      Except as modified by this letter, the terms, provisions and requirements of the Employment Agreement shall remain the same and In
        full force and effect in accordance with the terms and provisions thereof.

       

      
        	
                 

              	
                Very truly yours,

                 

                

                BioLineRx Ltd.

                

                 

                

                /s/ Philip Serlin

                By: Philip Serlin

                Title: Chief Executive Officer

                  

              
	 	 
	
                Accepted and agreed as of the date first written above:

                 

                

                /s/ Mali Zeevi

                  Mali ZeeviExhibit 4.6

    

    

    
      
        	
                
                  

                

              	
                
                  Modi'in Technology Park

                  2 HaMa'ayan Street

                  Modi'in 7177871, Israel

                   

                  

                  
                    Phone: 972-8-642-9100

                    Fax:      972-8-642-9101

                    web:      www.BioLineRx.com

                  

                

              

      

       

    

    September 24, 2020

    

    

    Re: Amendment to Employment Agreement

     

      

    Dear Abi:

    

    

    This letter shall serve as an amendment (the "Amendment") to that certain Employment Agreement, dated April 2, 2014, by and between
      BiolineRx Ltd. ("Bioline") and Abi Vainstein (the "Employee"), as amended, (the "Employment Agreement"). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Employment Agreement.

     

    Bioline and Employee hereby mutually agree to the following revisions to the Employment Agreement:

     

    Section 5.2 of the Employment Agreement shall be replaced with the following:

    

    

    "5.2          Termination.

    

                     (a)        In the event of termination without Cause (as defined below) by Bioline of Employee's employment, Bioline may terminate the Employment Agreement by giving the Employee prior written notice of 180 days.

     

    

                                                      (b)        In the event Employee resigns his employment for any reason that would constitute constructive dismissal under Israeli law, Employee may terminate the
      Employment Agreement by giving Bioline prior written notice of 60 days, but will be entitled to be compensated for a Notice Period of 180 days.

     

    

               (c)        In the event Employee resigns his employment for any reason other than as stated in section (b) above, Employee may terminate the Employment Agreement by
      giving Bioline prior written notice of 60 days. 

     

    Each of the notice periods in this Section 5.2 shall be deemed a "Notice Period" for the purpose of Section 5.4 below."

     

    

    Except as modified by this letter, the terms, provisions and requirements of the Employment Agreement shall remain the same and In full
      force and effect in accordance with the terms and provisions thereof.

    

    

    
      
        
          
            	
                     

                  	
                    Very truly yours,

                     

                    

                    BioLineRx Ltd.

                    

                     

                    

                    /s/ Philip Serlin

                    By: Philip Serlin

                    Title: Chief Executive Officer

                      

                  
	 	 
	
                    Accepted and agreed as of the date first written above:

                     

                    

                    /s/ Abi Vainstein

                      Abi VainsteinExhibit 4.8

  

  
    

    

    
      	
              
                

              

            	
              
                Modi'in Technology Park

                2 HaMa'ayan Street

                Modi'in 7177871, Israel

                 

                

                
                  Phone: 972-8-642-9100

                  Fax:      972-8-642-9101

                  web:      www.BioLineRx.com

                

              

            

    

     

    
      September 24, 2020

      

      

      Re: Amendment to Employment Agreement

      

      

      Dear Ella:

      

      

      This letter shall serve as an amendment (the "Amendment") to that certain Employment
        Agreement, dated January, 2017, by and between BiolineRx Ltd. ("Bioline") and Ella Sarani (the "Employee"), as amended, (the "Employment Agreement"). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them
        in the Employment Agreement.

       

      Bioline and Employee hereby mutually agree to the following revisions to the Employment
        Agreement:

      

      

      Section 5.2 of the Employment Agreement shall be replaced with the following:

      

      

      "5.2          Termination.

       

                       (a)        In the event of termination without Cause (as defined below) by Bioline of Employee's employment, Bioline may terminate the Employment Agreement by giving the Employee prior written notice of 180 days.

      

                       (b)        In the event Employee resigns his employment for any reason that would constitute constructive dismissal under Israeli law, Employee may terminate the Employment Agreement by giving Bioline prior written notice of 60 days,
        but will be entitled to be compensated for a Notice Period of 180 days..

       

      

                     (c)        In the event Employee resigns his employment for any reason other than as stated in section (b) above, Employee may terminate the Employment Agreement by giving Bioline
        prior written notice of 60 days. 

       

      Each of the notice periods in this Section 5.2 shall be deemed a "Notice Period" for
        the purpose of Section 5.4 below."

      

      

      
        Except as modified by this letter, the terms, provisions and requirements of the Employment Agreement shall remain the same and in full force and effect in accordance with the
          terms and provisions thereof.

         

        
          	
                   

                	
                  Very truly yours,

                   

                  

                  BioLineRx Ltd.

                  

                   

                  

                  /s/ Philip Serlin

                  By: Philip Serlin

                  Title: Chief Executive Officer

                    

                
	 	 
	
                  Accepted and agreed as of the date first written above:

                   

                  

                  /s/ Ella Sorani

                    Ella SoraniExhibit
10.1

 

FOMO
CORP.

 

SERIES
A PREFERRED TERM SHEET

 

This
term sheet is confidential, and none of its provisions or terms shall be disclosed to anyone other than an officer or director
of FOMO CORP. or its agent, adviser or legal counsel, unless required by law without the prior written consent of the parties.
Except for the confidentiality provision, this letter is non-binding and subject to the parties entering into formal agreements
setting forth their respective rights and obligations. Such agreements will contain customary representations, warranties, and
indemnifications. The material terms of the offering are set forth below:

 

Issuer:
FOMO CORP. (and together with its subsidiaries and affiliates, the “Company” or “FOMO” p/k/a
“2050 Motors, Inc.”)

 

Investor:
A Qualified Investor is being sought subject to approval by the Company (the “Investor”).

 

Amount:
up to $250,000.00

 

Securities:
Series A Preferred Stock convertible 1-50 into Common Stock and voting on an as converted basis (the “Offering”),
as set forth in the Securities Purchase Agreement (the “Securities Purchase Agreement”).

 

Closing
Date: The date of execution of the Securities Purchase Agreement and related Transaction Documents set forth therein.

 

Dividend:
$0.0035 per Series A Preferred Share (paid from time to time at the direction of the Board of Directors in cash or in kind;
such dividends shall accrue cumulatively irrespective of any payments authorized/effected by the Board of Directors and the Company).

 

Maturity
Date: Not Applicable

 

Redemption
Rights: None.

 

Issue
Price: The Investor shall purchase the Series A Preferred Stock at $0.10 per share, which is equivalent to $0.002 per share
on an as converted basis into common stock.

 

Warrants:
Investor shall receive 100% warrant coverage (12,500,000 warrants) with a three-year maturity, $0.003 strike price, and a
cashless exercise or a cash exercise subject to the underlying shares being registered with the SEC.

 

Optional
Conversion: At the option of the Investors, the Series A Preferred Shares may be convertible into shares of the Company’s
common stock (“Conversion Shares”) at any time. FOMO will irrevocably pledge xxx million common shares to buyer with
its transfer agent.

 

Mandatory
Conversion: None.

 

Lock-Up
Condition: All officers and major shareholders with greater than 5% of the Company shall be prevented from selling any shares
commencing on the initial closing date and ending 6 months after the final closing of the Offering, with any such sales subject
to Rule 144.

 

    	 

    	 

    

 

Anti-Dilution
Protection: At the class Leader’s election, the class may exercise one of the below:

 

	 	(i)	Weighted
    Average Ratchet: If the Company consummates an equity or equity-linked private financing (each, a “Subsequent Financing”)
    at any time so long as the Series A Preferred Shares are issued and outstanding, the Conversion Price of the Series A Preferred
    Shares will be adjusted to reflect any pricing lower than the conversion price of this Offering.
	 	 	 
	 	(ii)	Most
    Favored Nations: If the Company consummates an equity or equity-linked private financing (each, a “Subsequent Financing”)
    at any time subsequent to the closing of this Offering, the Investors may exchange any outstanding Series A Preferred Shares,
    on a $1 for $1 basis based upon the principal amount of the Series A Preferred Shares being exchanged plus any accrued and
    unpaid dividends, for the securities in the Subsequent Financing. The Company shall notify the Investors of such Subsequent
    Financing and the Investor shall have five (5) business days to elect to exchange the Series A Preferred Shares into the terms
    of the Subsequent Equity Financing.
	 	 	 
	 	(iii)	Right
    of First Refusal: In the event the Company proposes to offer equity or equity-like securities to any person (other than
    an underwritten public offering), the Investors shall have the right to purchase their pro rata portion of such shares.

 

Change
of Control: Not applicable.

 

Use
of Proceeds: General corporate purposes including growth of operations and working capital. No convertible debt will be retired
with use of funds.

 

Transfer
Restriction: The Preferred Stock may not be sold, pledged, or otherwise transferred by the Investors without the prior written
consent of the Company, which will not be unreasonably withheld.

 

Expenses:
The Company will bear all of the expenses in connection with this transaction, including but not limited to the reasonable
legal (not to exceed $3,000 in total including other participating investors), due diligence and documentation expenses of the
Investors.

 

Due
Diligence:The completion of the transaction described in this agreement shall be subject to the Lead Investor’s
satisfaction with the results of its due diligence investigation in its sole discretion.

 

Expiration:
This term sheet will expire if not executed by all parties on or before February 10, 2021.

 

Security
Interest: Not applicable.

 

Information
Rights: The Company will deliver to the Investors annual audited and quarterly unaudited financial statements, annual budgets
and other information reasonably requested by such investors within 60 days of the first closing of this Offering.

 

Confidentiality:
The parties hereto (including their directors, partners, officers, employees and agents) agree to retain in confidentially
information contained herein and any information transmitted between the parties pursuant to it, and further agree that they will
not use for their own benefit and will not use or disclose to any third party of, any information obtained from or revealed by
the Company.

 

Severability:
If any provision of this term sheet is invalid or unenforceable for any reason, such provision will be construed to have been
adjusted to the minimum extent necessary to cure such invalidity or unenforceability. The invalidity or unenforceability of one
or more of the provisions contained herein will not have the effect of rendering any other provisions of this term sheet invalid
or unenforceable whatsoever.

 

    	 

    	 

    

 

Governing
Law: The definitive transaction documents will be governed by the laws of the state of California, without regard to the principles
of conflict of laws thereof.

 

If
this term sheet correctly expresses our mutual intentions, please execute and return to the undersigned.

 

	By:	 	 
	Name:
    	 	 

 

ACCEPTED
AND AGREED TO: as of _______________, 2021

 

[INVESTOR]

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

FOMO
CORP.

 

	By:	 	 
	Name: 	Vikram
    Grover	 
	Title:	Chief
    Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}]]